raxibacumab

07/01/2010 - "Raxibacumab is a promising prophylactic and therapeutic for inhalational anthrax."
07/09/2009 - "A single dose of raxibacumab improved survival in rabbits and monkeys with symptomatic inhalational anthrax. "
07/01/2010 - "anthracis might be targeted effectively with raxibacumab, which is a blocking human mAb. AREAS COVERED IN THIS PAPER: To discuss the results of experimental and human studies evaluating raxibacumab for inhalational anthrax. "
01/01/2020 - "This finding suggests that combining raxibacumab with AVA might provide added benefit in postexposure prophylaxis against inhalational anthrax. "
01/01/2020 - "Raxibacumab: a panacea for anthrax disease?"

12/01/2015 - "Using this model, we have now studied raxibacumab with 24 h edema toxin challenges (Study 1), and lethal and edema toxin challenges together (Study 2). "
12/01/2015 - "In Study-2, survival rate and time increased with HS and raxibacumab at 0 h (4/4) or 6 h after (3/3) beginning lethal and edema toxin compared to HS [0/5; 71.5 h (65 to 93)] (p = 0.01 averaged over raxibacumab groups). "
12/01/2015 - "Compared to HS, HS with raxibacumab treatment at or 6 h after the beginning of edema toxin increased MAP and survival rate (6/7 and 7/8, respectively) and time [96.0 h (39.5 to 96.0) and 96.0 h (89.5 to 96.0), respectively]; (p ≤ 0.05). "
12/01/2015 - "Using our canine model, we have now studied raxibacumab with 24h edema toxin challenges (Study-1), and lethal and edema toxin challenges together (Study-2). "
12/01/2015 - "Raxibacumab augments HS and improves survival during shock with lethal and edema toxin."

12/01/2021 - "The proposed dosing regimens take into account effects of body weight and maturation processes on the elimination of raxibacumab."
12/01/2021 - "Interindividual variability in raxibacumab vs. time profiles could partially be accounted for by differences in body weight."
02/01/2015 - "anthracis spores were randomized to receive 3 daily intragastric LVX doses of 50 mg/kg of body weight, with the first LVX dose administered just prior to administration of a single intravenous dose of placebo or 40 mg/kg raxibacumab. "
07/09/2009 - "Animals with detectable protective antigen in serum, a significant increase in temperature, or both received a single intravenous bolus of placebo or raxibacumab at a dose of either 20 mg per kilogram of body weight or 40 mg per kilogram. "

12/01/2015 - "Raxibacumab augments hemodynamic support and improves outcomes during shock with B. "
12/01/2015 - "Raxibacumab augments HS and improves survival during shock with lethal and edema toxin."
01/01/2021 - "anthracis infection, and Raxibacumab and AIGIV were compared to placebo when combined with standard hemodynamic support in a 96 h canine model of anthrax toxin-associated shock. "

01/01/2015 - "Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration "Animal Rule"."
01/01/2021 - "Among the three antibacterial mAbs, raxibacumab (ABthrax®/ Anthrin®) and obiltoxaximab (Anthim®) are indicated for the treatment and prophylaxis of inhalation anthrax due to Bacillus anthracis; bezlotoxumab (Zinplava®) is used to reduce the recurrence of Clostridium difficile infection. "